NATO’s saber-rattling only impairs security of alliance's members — diplomatRussian Politics & Diplomacy May 22, 20:20
Russian sledge hockey team may compete in 2018 Paralympics — IPCSport May 22, 18:53
PM Medvedev says envoy’s murder 'left imprint' on Russian consulate’s work in TurkeyRussian Politics & Diplomacy May 22, 18:40
Peruvian fire-fighting service wants to buy Russian Mi-171 helicoptersBusiness & Economy May 22, 18:00
Putin sets task of accelerating work on super-heavy rocketScience & Space May 22, 17:55
Russian PM comments on decision to remove trade restrictions with TurkeyBusiness & Economy May 22, 17:39
Russia and its EU partners discuss entry point for Turkish Stream’s second lineBusiness & Economy May 22, 17:38
Austrian chancellor to address SPIEF-2017 on June 2Business & Economy May 22, 17:00
Russian air defense weaponry sparks interest at Minsk military showMilitary & Defense May 22, 16:54
TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.
- Study data to be presented (Presentation date / time: USA Eastern time zone)
Abstract No.: 370
Title: AJM300, an Oral alpha 4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-Blind, Placebo- Controlled* Phase 2A Study
Presentation date / time: May 4, 2014, 1:36-1:46 PM, Oral presentation
*Randomized double-blind, placebo-controlled study
Randomized double-blind, placebo-controlled study is a method of study to objectively evaluate the efficacy of medicine. In the study, neither investigators nor patients know which the patient takes a placebo (a mimic preparation that looks like a study drug but contains no active ingredient) or the study drug.
About Ajinomoto Pharmaceuticals Co., Ltd.
Representative Director,President & CEO: Takashi Nagamachi
Headquarters, Chuo-ku, Tokyo
Hajime Ito, Corporate Planning Dept, Ajinomoto Pharmaceuticals Co., Ltd.